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Aptamers targeting reverse transcriptase (RT)
from HIV-1 inhibit viral replication in vitro, pre-
sumably by competing with binding of the
primer/template complex. This site is not tar-
geted by the currently available small-molecule
anti-HIV-1 RT inhibitors. We have identified
SY-3E4, a small-molecule inhibitor of HIV-1
RT, by applying a screening assay that utilizes
a reporter-ribozyme regulated by the anti-HIV-
1 RT aptamer. SY-3E4 displaces the aptamer
from the protein, selectively inhibits DNA-de-
pendent, but not RNA-dependent, polymerase
activity, and inhibits the replication of both the
wild-type virus and a multidrug-resistant strain.
Analysis of available structural data of HIV-1 and
HIV-2 RTs rationalizes many of the observed
characteristics of the inhibitory profiles of SY-
3E4 and the aptamer and suggests a previously
not considered region in these RTs as a target
for antiviral therapy. Our study reveals unex-
plored ways for rapidly identifying alternative
small-molecule target sites in proteins and illus-
trates strategies for overcoming resistance-
conferring mutations with small molecules.
INTRODUCTION
It is estimated that ‘‘chemical space’’—the total possible
number of small carbon-based drug-like compounds
with molecular masses of up to 500 Da—might be 1060
or greater [1, 2]. In contrast, fewer than 30 million mole-804 Chemistry & Biology 14, 804–812, July 2007 ª2007 Elseviercules are registered in Chemical Abstracts, and only a sub-
set of these has biological relevance [3]. This raises the
question of how one might effectively explore chemical
space to identify molecules of biological or medicinal in-
terest. Toward this goal, we have developed approaches
that combine Darwinian evolution of biomolecules with
small-molecule screening [4–6]. Biomolecules continu-
ously adapt their functional properties to external condi-
tions by mechanisms through which superior features
emerge from a combination of genetic alterations and sur-
vival of selective pressures. These features are passed on
to subsequent generations. The same principles can be
applied in vitro to select for aptamers from libraries with
a molecular diversity of up to 1016 different structured nu-
cleic acid sequences, the highest degree of diversity cur-
rently amenable to screening. Aptamers can serve as
specific inhibitors of virtually any given protein target,
but the main obstacle to achieving broadly applicable
inhibition of target proteins in cells, tissues, and whole
organisms by aptamer technology is delivery. In addition,
these approaches have limited, if any, clinical use. For
such purposes, drug-quality small molecules are highly
advantageous compared to any nucleic acid- or biopoly-
mer-based inhibitor, both as research tools and as starting
points for drug development. Therefore, we have devel-
oped strategies that enable the conversion of an ap-
tamer/protein complex into a small organic inhibitor by
screening small-molecule libraries for compounds that
displace the aptamer from its target and adopt its inhibi-
tory activity [5, 6]. This allows for small molecules with
similar inhibitory activities as the parent aptamer to be
searched for directly. Here, we have used this approach
to explore the possibility of identifying novel classes of in-
hibitors targeting reverse transcriptase of HIV-1 (HIV-1 RT)
at different sites than the currently available anti-HIV-1 RT
inhibitors. Based on a structurally well-characterized RNALtd All rights reserved
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we identified such a small-molecule inhibitor and rational-
ized its binding and inhibitory characteristics by using
crystallographic and mutant data. Our results show that
novel types of active small molecules can be identified
with the aid of reporter ribozyme probes against estab-
lished protein targets. The newly identified inhibitor cir-
cumvents some of the current limitations associated
with small-molecule HIV-RT inhibitors caused by drug-
resistant mutations and might provide a previously unex-
plored opportunity for antiviral therapy.
RESULTS
Converting the Anti-HIV-1 RT Aptamer into
a Small Molecule
To convert the inhibitory profile of the anti-HIV-1 RT ap-
tamer into a drug-like inhibitor, we established a screening
assay based on a rationally designed allosteric hammer-
head ribozyme that is able to detect HIV-1 RT with high
selectivity [7]. The ribozyme is regulated by a variant of
a small aptamer that forms a pseudoknot structure in the
presence of the protein [8], rendering the ribozyme inac-
tive, but folds into a stem-loop structure with an internal
bulge in its absence [7], resulting in ribozyme activation
(Figure 1A; see Figure S1 in the Supplemental Data avail-
able with this article online). This allosteric ribozyme ex-
hibits extraordinary selectivity for HIV-1 RT, as it cannot
be regulated by RTs from even closely related viruses
such as RT from HIV-2. In its active form, the ribozyme
cleaves an RNA substrate labeled with a fluorophor on its
50 end and a quencher molecule, tetramethylamino rhoda-
mine, on its 30 end. Due to fluorescence resonance energy
transfer (FRET), fluorescence of the uncleaved substrate is
quenched [5], whereas cleavage results in dissociation of
the substrate fragments and fluorescence dequenching.
The general principles of allosteric ribozymes have been
utilized in various sensors and reporter applications [9–13].
By screening a diverse library of synthetic chemicals
with this assay, we identified a series of compounds as
initial hits that were able to reactivate the ribozyme, pre-
sumably by displacing the aptamer domain from the
bound RT (Figure S1). Based on their behavior in the re-
porter ribozyme assay, the most promising compounds,
SY-3E4 and SY-2E10, both representing substituted
N,N0-diphenylurea derivatives, were selected for synthe-
sis and further studies (Figure 1B; Supplemental Data
and Figure S2).
To confirm that SY-3E4 displaces the aptamer from the
protein rather than activating the reporter ribozyme by
a different mechanism, we performed an assay in which
the complex of HIV-1 RT and the isolated 50-32P-labeled
aptamer was immobilized on nitrocellulose in the pres-
ence of increasing concentrations of the compound. As
a control, the same experiment was done with nevirapine,
a small molecule that binds HIV-1 RT in a way that does
not interfere with aptamer binding (Figure 1C). As evident,
the amount of aptamer/protein complex is reduced at SY-
3E4 concentrations above 50 mM, whereas high concen-Chemistry & Biology 14,trations of nevirapine had no influence on complex stabil-
ity. These data show that the screening assay identified
SY-3E4 by a mechanism by which the compound inter-
fered with the formation of the aptamer/protein complex.
RT Inhibition Is Template Dependent
We analyzed the inhibitory potential of these compounds
in a primer-elongation assay (Figure 1D) with radiolabeled
primers, dNTPs, either RNA or DNA templates, and either
reverse transcriptase or DNA polymerase from various or-
ganisms. Table 1 summarizes the IC50 values obtained for
the two molecules in both RNA- and DNA-templated
primer-elongation assays (also see Figure S5).
Impressively, both compounds showed marked differ-
ences in their inhibitory potential depending on whether
RNA or DNA was used as a template in the primer-elonga-
tion assay. With HIV-1 RT, SY-3E4 exhibited the lowest
IC50 values of 2.1 mM, but only in the DNA-dependent
(DD) primer elongations. In the RNA-dependent (RD) as-
say, the inhibitory potential of this compound was reduced
almost 70-fold. In contrast, while SY-2E10 also inhibited
HIV-1 RT with an IC50 value of 3.7 mM, its discrimination
between DD and RD assays was less than 3-fold. A very
similar inhibitory profile was also observed when using
HIV-2 RT as a target. SY-3E4 inhibits HIV-2 RT with an
IC50 value of 9.4 mM in DD polymerization, and it discrim-
inates between DD and RD polymerizations 17-fold.
SY-2E10 showed an IC50 value of 5.1 mM, with 2-fold dis-
crimination between DD and RD polymerizations.
We also performed control reactions with other reverse
transcriptases and DNA polymerases (Table 1). Inhibition
of RT from avian myoblastoma virus (AMV) by SY-3E4
was marginal in both DD and RD primer extensions
(64mM), whereas SY-2E10 showed an IC50 value of 7.2mM
for DD polymerizations, with <4.5-fold discrimination to
the disadvantage of the RD reaction. SY-3E4 also ex-
hibited a moderate IC50 value of 21 mM when Moloney
murine leukemia virus (MMLV) RT was used in the DD
reaction, with 2-fold discrimination to the disadvantage
of the RD polymerization. In contrast, Klenow fragment
DNA polymerase (KF) was insignificantly inhibited by
SY-3E4 and was moderately inhibited by SY-2E10. Poly-
merase b (Polb) was moderately inhibited by SY-3E4,
whereas the IC50 value of SY-2E10 was 12.3 mM (Table 1).
Taken together, these data show that, particularly,
SY-3E4 specifically inhibits the DNA-dependent, but not
RNA-dependent, primer-elongation activity of reverse
transcriptases from HIV-1 and HIV-2. Other RTs or DNA
polymerases are either not targeted or only marginally
blocked by this inhibitor. The selectivity of SY-2E10 for
HIV RTs and also for the used template was much less
pronounced. This inhibitor also showed weak inhibition
of RTs and DNA polymerases from other organisms.
SY-3E4 Inhibits HIV-1 Replication for Wild-Type
and a Multidrug-Resistant Strain
SY-3E4, the identified compound that showed the best
specificity and IC50 values for HIV-1 and HIV-2 RTs, was
then assayed for its ability to reduce HIV-1 replication in804–812, July 2007 ª2007 Elsevier Ltd All rights reserved 805
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(A) Schematic for the HIV-1 RT-responsive hammerhead ribozyme used in the screening assay. In the presence of HIV-1 RT, the aptamer sequence
(blue) adopts a pseudoknot structure, disrupting the formation of stem II (left). The additional GC pair was introduced to enforce the formation of the
stem-loop structure (left) in the absence of HIV-1 RT (also see Figure S1C for sequences).
(B) Chemical structures of the obtained compounds, SY-3E4 and SY-2E10.
(C) SY-3E4 displaces the isolated aptamer complexed to HIV-1 RT. Upper panel: duplicate dot-blot analysis of 50-32P-labeled aptamer/RT complex
retained on nitrocellulose filters at increasing concentrations of SY-3E4 and nevirapine (Nv). Lower panel: quantification of the dot-blot analysis by
PhosphorImaging. Error bars represent standard deviations for duplicates.
(D) Representative example showing the inhibition of DNA polymerase activity of HIV-1 RT by small-molecule inhibitors. In the presence of HIV-1 RT,
the 50-end-labeled primer is extended by employing either a DNA or RNA template (top panel). The control lane in the absence of HIV-1 RT () shows
the primer position. Polymerization reactions were inhibited by the addition of increasing concentrations of inhibitors (bottom panel, right lanes). The
inhibitor concentrations ranged from 0.5 mM to 50 mM.tissue culture cells. At concentrations between 10 and
100 mM, no cytotoxicity was observed for SY-3E4 and SY-
2E10 (data not shown). We then measured the inhibitory
potential of all compounds in a self-inactivating HIV vector
system [14] (Figure S3A). SY-3E4 showed substantial re-
duction of reporter gene expression in a concentration-
dependent manner. However, with SY-2E10, the same
level of luciferase activity as in the negative control exper-
iments was observed, indicating that SY-2E10 has no ef-
fect in this reporter gene assay (Figure S3B). At present,
we do not have an explanation for the lack of in vivo inhib-
itory activity of SY-2E10. Possible reasons for this obser-
vation may be poor uptake of this compound by the cells
or a short half-life under these conditions. Half-maximal806 Chemistry & Biology 14, 804–812, July 2007 ª2007 Elseviereduction of luciferase expression by SY-3E4 was ob-
tained at 5.3 mM, a value that is in the same order of
magnitude as the IC50 values measured in the primer-
elongation assays in vitro.
Encouraged by these results, we next investigated the
effect of SY-3E4 on the expression of a luciferase reporter
gene under the control of the HIV-1 long terminal repeat
(LTR) promoter [15] in TZM cells infected with the wild-
type HIV-1 strain NL4-3. As shown in Figure 2A, luciferase
gene expression was dramatically reduced in the pres-
ence of SY-3E4 in a concentration-dependent fashion,
reaching complete inhibition at 30 mM concentrations,
and a half-maximal reduction at less than 20 mM. These
data are in accordance with the results shown inr Ltd All rights reserved
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Alternative Small-Molecule Target Sites in HIV-RTTable 1. IC50 Values of SY-3E4 and SY-2E10 for Different DNA Polymerases and Reverse Transcriptases
SY-3E4 SY-2E10
RT Strain Template IC50 (mM)
a
HIV-1 DD 2.1 ± 0.6 3.7 ± 0.1
RD 145 ± 5.1 10.8 ± 0.9
HIV-2 DD 9.4 ± 0.2 5.1 ± 0.1
RD 160 ± 19.1 10.3 ± 0.9
AMV DD 64.1 ± 2.6 7.3 ± 0.2
RD 63.7 ± 7.8 32.0 ± 4.8
MMLV DD 21.2 ± 0.9 12.2 ± 0.1
RD 42.5 ± 1.2 16.4 ± 0.4
KF DD 99.7 ± 3.3 22.8 ± 0.5
Polb DD 30.4 ± 0.8 12.3 ± 0.1
DD, DNA-dependent DNA polymerase activity; RD, RNA-dependent DNA polymerase activity.
a The mean values ± standard deviations obtained from two independent experiments are shown.Figure S3B. In contrast, SY-2E10 was again inactive in this
assay, as expected from the results with the self-inactivat-
ing HIV vector system. In a second experiment, we inves-
tigated the effect of the selected compounds on the num-
ber of HIV-1-infected cells. To this end, we grew HIV-1 by
coculturing an infected and uninfected T cell line in the
presence or absence of drug and determined the titer
again by using TZM cells, which express b-galactosidase
under the control of the HIV-1 LTR promoter, thus en-
abling colorimetric detection and enumeration of the
HIV-1-infected cells. The infectivity of intact HIV-1 NL4-3
virus was arbitrarily set at 100%. In accordance with the
previous experiments, SY-3E4 reduced the number of
infected cells considerably, in contrast to SY-2E10. Com-
plete loss of infectivity was observed with 30 mM SY-3E4,
with an IC50 value of 15 mM (Figure 2B).
To investigate the effect of SY-3E4 on the replication of
a multidrug-resistant strain of HIV-1, we performed an in-
hibition experiment with the virus TN6-P5-5, carrying the
protease- and RT genes from a highly resistant, patient-
derived HIV-1 in the genetic background of the NL4-3
strain (see Supplemental Data for mutations in RT of
TN6-P5-5). This strain had been shown to be resistant
against a series of NNRTI and NRTI drugs (e.g., AZT,
Tenofovir, and Efavirenz), and its resistance profile was
confirmed in our experiments by using a direct compari-
son with NL4-3 (Figure 2C, middle panels). Importantly,
however, SY-3E4 showed essentially no difference in its
ability to inhibit wild-type HIV-1 and the multidrug-resis-
tant strain (Figure 2C, left panel), indicating that it is not
affected by the resistance-conferring mutations in TN6-
P5-5. As before, SY-2E10 had no effect on NL4-3, nor
on the mutant strain.Chemistry & Biology 14,SY-3E4 Competes with Primer/Template Complex
Binding to HIV-1 RT
We have previously shown that the addition of a DNA
primer/template complex [16] results in competitive dis-
placement of the HIV-1 RT reporter ribozyme from the
enzyme, leading to reactivation of the ribozyme cleavage
reaction [7]. Therefore, to further elucidate the possible
mechanism of action of SY-3E4, we investigated whether
the inhibitor would also be able to compete with primer/
template complexes bound to HIV-1 RT. We performed
an electrophoretic mobility shift assay (EMSA) in which
the amounts of primer/template/HIV-1 RT complexes ob-
tained at various concentrations of SY-3E4 were quanti-
fied. As shown in Figure 2D, SY-3E4 was able to compete
with the primer/template complex for HIV-1 RT binding,
whereas nevirapine, an NNRTI that binds outside the
primer/template site, was inactive. However, competition
by SY-3E4 was efficient only at concentrations above
100 mM. Furthermore, both the DNA primer/DNA and RNA
template complexes were competed. Competition of the
DNA primer/RNA template complex was even slightly
more efficient, with approximately 200 mM half-maximal
concentration of competition, than the DNA primer/DNA
template complex (500 mM). Thus, the half-maximal con-
centration of competition measured for the DNA primer/
RNA template complex displacement matches well with
the IC50 value obtained for the corresponding HIV-1 RT
inhibition reaction (Table 1). The same is true when the
aptamer was used as a competitor (Figure 2D, left panel,
lanes 10 and 18; right panel, lane A), indicating that, in
these cases, the inhibitory mechanism is largely deter-
mined by competition with the primer/template complex.
In contrast, the half-maximal concentration of competition804–812, July 2007 ª2007 Elsevier Ltd All rights reserved 807
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Alternative Small-Molecule Target Sites in HIV-RTFigure 2. Inhibition of HIV-1 Replication by Small-Molecule Inhibitors
(A) HIV-1 replication was investigated in TZM reporter cells infected with HIV-1 strain NL4-3 wild-type virus in the presence of 3E4 (filled circles) or
2E10 (filled triangles), the negative control (multiplication signs), or AZT as the positive control (open circles). The mean percentage of luciferase
marker gene expression compared with untreated control cells from at least two replicate infections is shown.
(B) TZM cells were infected with HIV-1 strain NL4-3, and numbers of infected cells were counted after staining with b-galactosidase substrate after
48 hr. Values are expressed as the percentage of the number of infected cells without inhibitors, which was set to 100%. The mean of duplicates is
shown. 3E4, filled circles; 2E10, filled triangles; negative control, multiplication signs; and AZT, open circles.
(C) Comparison of inhibition of the wild-type strain NL4-3 (gray bars) and the multidrug-resistant mutant TN6-P5-5 (black bars) with various inhibitors.
Inhibitor concentrations were matched according to the different IC50 values (from right to left: SY-2E10: 0.1, 1, 5, 10, 20 mM; Efavirenz: 0.1, 1.0, 10,
100, 1000 nM; Tenofovir: 0.001, 0.01, 0.1, 1, 10 mM; AZT: 0.001, 0.01, 0.1, 1, 10 mM; SY-3E4: 0.1, 1, 5, 10, 20 mM). The y axis shows the percent in-
fectivity of control, where the control is the parallel infection with DMSO-treated virus, which was arbitrarily set at 100%. Error bars represent standard
deviations for triplicates.
(D) SY-3E4 interferes with primer/template binding to HIV-1 RT at high concentrations. Left panel: gel shift of radiolabeled primer (P), complexed to the
DNA template (lanes 2–10) or RNA template (lanes 11–18), respectively, in the absence (PT) and presence of HIV-1 RT (PT-RT complex). Lanes 3–10:
complex of DNA template, primer, and HIV-1 RT in the presence of 0 (lane 3), 50 mM (lane 4), 100 mM (lane 5), 200 mM (lane 6), 500 mM (lane 7), 1 mM
(lane 8) SY-3E4; 1 mM nevirapine (lane 9); and 0.5 nM aptamer (lane 10). Lanes 11–18: complex of RNA template, primer, and HIV-1 RT in the presence
of 0 (lane 11), 50 mM (lane 12), 100 mM (lane 13), 200 mM (lane 14), 500 mM (lane 15), 1 mM (lane 16) SY-3E4; 1 mM nevirapine (lane 17); and 0.5 nM
aptamer (lane 18). Right panel: ratio of primer/template complex bound to HIV-1 RT quantified from the gel-shift experiments. White bars, primer-DNA
template; black bars, primer-RNA template. C: DMSO negative control, 50 mM (lane 1), 100 mM (lane 2), 200 mM (lane 3), 500 mM (lane 4), 1 mM (lane 5)
SY-3E4; 1 mM nevirapine (N); and 0.5 nM aptamer (A). Error bars represent standard deviations for duplicates.808 Chemistry & Biology 14, 804–812, July 2007 ª2007 Elsevier Ltd All rights reserved
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200-fold higher than the IC50 value, which means that
the mechanism of inhibition by SY-3E4 cannot solely be
explained on the basis of competition with the primer/
template complex.
Figure S4 shows the structure of HIV-1 RT in a trapped
complex with a DNA primer/RNA template hybrid [17] and
summarizes known features of the polymerization mecha-
nism. On the basis of currently available data, it is not pos-
sible to explain the inhibitory preference of SY-3E4 for the
DD reaction in molecular detail. However, the RNA in the
RNA/DNA complex is only partly present during catalysis,
the partial complex is much more transient than the DNA/
DNA complex, and the RNA-dependent polymerization ef-
ficiency is higher (Figure S4). These features suggest that
the RNA/DNA complex might provide a more difficult tar-
get for small-molecule interference and competition than
the more stable and catalytically less efficient DNA/DNA
complex.
Rationalization of Inhibitor Characteristics
and Target Sites
Taken together, SY-3E4 exhibits the following character-
istics: (1) the inhibitor displaces the anti-HIV-1 RT aptamer
bound to its target; (2) it inhibits RTs from both HIV-1 and
HIV-2, whereas the aptamer inhibited only HIV-1 RT, and
(3) it predominantly inhibits DNA-dependent polymeriza-
tion; (4) SY-3E4 inhibition is not affected by the common
NRTI- and NNRTI-resistant mutations; and (5) SY-3E4
competition of primer/template complexes occurs only
at high concentrations and does not discriminate between
DNA and RNA templates.
Based on the analysis of available crystallographic
structures and mutant data, characteristic features of the
aptamer and SY-3E4 inhibitor profiles can be well rational-
ized. Figure 3A shows a view of a high-resolution structure
of HIV-1 RT [18]. The representation highlights the fingers,
palm, thumb, and RNase H domains in the p66 subunit of
the enzyme. Furthermore, it shows the locations of the
NRTI drug-binding site, indicated by bound dNTP [19],
and the NNRTI-binding site with bound nevirapine [18].
For residue mapping analysis, we have transferred the
bound aptamer from its low-resolution complex with HIV-
1 RT [20] to the high-resolution structure [18] after optimal
superposition of protein backbone atoms. In Figure 3B,
sites of natural mutations causing NRTI and NNRTI drug
resistance [21] are displayed. NRTI drug-resistant muta-
tions primarily map to the fingers domain, and NNRTI
drug-resistant mutations map to the palm and thumb do-
mains (Table S1). No drug-resistant mutations were found
in the aptamer-binding region, however. Therefore, the
most plausible explanation for aptamer replacement by
SY-3E4 is that the inhibitor also binds to the aptamer-bind-
ing region. This is supported by the finding that SY-3E4
binding was not affected by known drug-resistant muta-
tions, which all reside outside the aptamer-binding site.
An important difference in specificity between SY-3E4
and the aptamer is that SY-3E4 inhibits both HIV-1 and
HIV-2 RT, whereas the aptamer only binds HIV-1 RTChemistry & Biology 14,[22]. In Figure 4A, changes in surface-residue positions
between HIV-1 and HIV-2 RT [23] are mapped. As can
be seen, the region in HIV-2 RT that corresponds to the
aptamer-binding site in HIV-1 RT contains many sur-
face-residue replacements relative to HIV-1 RT that
include aptamer contact residues. The nonconservation
of residues mediating HIV-1 RT/aptamer interactions ex-
plains why the aptamer does not bind to HIV-2 RT.
Figure 3. Structure of HIV-1 RT, Location of Drug-Resistant
Mutations, and the Aptamer-Binding Site
(A) Structural overview of HIV-1 RT, a heterodimer composed of two
subunits, the catalytic active p66 and the p51 subunit. In p66, the fin-
gers (blue), palm (carnation), and thumb (cyan) domains are high-
lighted. The polymerase active site is located in the palm domain.
The substrate analog dTTP (space-filling representation, red) binds
at the same polymerase active site location as NRTI drugs. By con-
trast, NNRTI drugs such as nevirapine (space-filling, light blue) bind
at the interface between the palm and thumb domains. Also high-
lighted is the RNase H (green) domain that removes RNA during re-
verse transcription. The domains responsible for the polymerase and
endonuclease activities are linked by a connecting domain (yellow).
The p51 subunit (gray) does not participate in catalytic activities.
(B) Residues that are hot spots for natural mutations causing NRTI
drug resistance (red) are mainly located in the fingers domain, whereas
mutated residues causing NNRTI drug resistance (light blue) are dis-
tributed over parts of the palm and thumb domains. Sites of mapped
NRTI and NNRTI drug-resistant mutations are colored in red and light
blue, respectively. The aptamer (magenta) extends along the nucleic
acid-binding cleft and overlaps with the primer/template-binding
site, but does not protrude into the palm and polymerase active site
region. Mapping of mutants and the aptamer-binding site reveals
that the NRTI/NNRTI drug-resistant sites and the aptamer-binding
site are located in distinct regions of HIV-1 RT.804–812, July 2007 ª2007 Elsevier Ltd All rights reserved 809
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in HIV-1 and HIV-2 RT, the aptamer-binding region con-
tains clusters of residues that are conserved in both en-
zymes. A cavity highlighted in Figure 4B presents a likely
site for small-molecule binding. This deep and largely hy-
drophobic pocket is formed by residues that are con-
served in HIV-1 and HIV-2 RT. While identification of the
exact SY-3E4-binding site awaits crystallographic analy-
sis of an RT/SY-3E4 complex (or transfer NOE experi-
ments), we can conclude that the aptamer-binding sur-
face in HIV-1 RT contains a region that is conserved in
HIV-2 RT and provides an attractive and previously unob-
served target site for small molecules.
DISCUSSION
In this study, we have identified a novel small-molecule
inhibitor of HIV-1 and HIV-2 RT through a displacement as-
say with an HIV-1 RT-specific aptamer. The data reported
above show that this assay based on the RT-responsive
reporter ribozymes was able to quickly and robustly iden-
tify a previously unknown, to our knowledge, inhibitor of
Figure 4. Mapping of HIV-RT Surface Residues
Shown is a solvent-accessible surface representation of HIV-1 RT in
the same orientation as in Figure 3; the p66 and p51 subunits are col-
ored green and blue, respectively.
(A) Surface-residue variation between HIV-1 RT and HIV-2 RT. Residue
positions that are not conserved are shown in white, and the aptamer is
shown in magenta. There are extensive residue changes between HIV-
1 RT and HIV-2 RT involving aptamer contact residues in HIV-1 RT.
(B) Depiction of an attractive candidate site for small-molecule binding
(orange), a deep pocket formed by residues conserved in HIV-1 RT and
HIV-2 RT. This pocket is located within the aptamer-binding region.810 Chemistry & Biology 14, 804–812, July 2007 ª2007 ElsevieHIV-1 replication. SY-3E4 might serve as an interesting
lead compound to find small molecules that are even
more potent in reducing retrovirus replication. The finding
that SY-3E4 inhibits both HIV-1 and HIV-2 RT, with moder-
ate 4.5-fold discrimination of SY-3E4 in favor of HIV-1 RT,
is interesting because the aptazyme displaced by this
compound discriminates between these related enzymes
quite well [7]. Analysis of surface-residue conservation in
HIV-1 and HIV-2 RT explained the specificity of the ap-
tamer. Another key finding has been that the function
of SY-3E4 was not affected by known drug-resistant
mutations, and this molecule may thus provide new
opportunities for antiviral HIV therapy. The inhibitor char-
acteristics of the aptamer and SY-3E4 are well in accord
with available structural data, and, on the basis of our anal-
ysis, we can point at a region in HIV-1 and HIV-2 RT outside
the polymerase active site and its vicinity that provides
a promising target site for small molecules to interfere
with the formation of the primer/template complex.
The ability of SY-3E4 to compete with primer/template
complex binding to HIV-1 RT at high concentrations is
consistent with the proposed presence of a small-mole-
cule binding region outside the polymerase active site.
The concentration of SY-3E4 required to inhibit the
DNA-dependent polymerase activity was considerably
lower than the one needed to replace the corresponding
primer/template. This suggests that complete replace-
ment of the primer/template is not required for the inhibi-
tion of DNA-dependent polymerase activity by SY-3E4.
By contrast, the SY-3E4 concentrations required to inhibit
RNA-dependent polymerase activity or replace primer/
template were comparable in magnitude, which indicates
that RNA-dependent polymerase activity is more difficult
to inhibit by a small molecule.
The mechanism of interference with HIV-1 RT activity
proposed here for SY-3E4 has not yet been explored for
targeting, which is remarkable in light of a finding by Fisher
and colleagues regarding the emergence of resistance to
primer/template-competing inhibitors [24]. This study re-
ported that mutations in HIV-1 RT that confer resistance
to inhibitory aptamers [25] result in replication-defective
HIV-1 by affecting primer/template interactions. The two
mutants, N255D and N265D, map to the RT thumb domain
and contact the primer/template. A subsequent study
showed that these aptamer-resistant mutations retain
their susceptibility to all NRTIs and NNRTIs tested in vitro
[26]. In addition, the N265D mutation severely affected
processivity of DNA-dependent DNA polymerase activity,
but not that of RNA-dependent DNA polymerase activity.
The N255D mutation affected the processivity of both
activities severely [27]. Thus, the aptamer-resistant-con-
ferring mutation N265D and compound SY-3E4 display
a similar inhibitory profile. Considering the drug-resistant
mutation-independent mechanism of SY-3E4 inhibition,
it is possible that SY-3E4 treatment might also induce mu-
tations in HIV-1 RT (like the aptamer) that could be suicidal
or compromise enzymatic activity. Together with the re-
cent finding that anti-RT aptamers are able to block HIV
replication more potently than shRNAs [28–30], this wouldr Ltd All rights reserved
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SIGNIFICANCE
We have used an aptamer-displacement assay based
on a highly modular and generally applicable protein-
responsive ribozyme to identify a small-molecule
antagonist for the human immunodeficiency virus
type-1 reverse transcriptase (HIV-1RT). Advancing be-
yond proof of principle, we show that this compound
can inhibit the replication of HIV-1wild-type and amul-
tidrug-resistant strain. Thus, the compound’s function
is not affected by known drug-resistant mutations. An
analysis of available crystallographic data ofHIV-1 and
HIV-2 RTs, complemented by characteristics of the in-
hibitory profile of the compound, identifies a region in
these proteins as a previously unconsidered drugable
interface that can be targeted by a small molecule.
Since there are currently no small-molecule inhibitors
available in the clinic that target this new site, our find-
ings represent a major advance in the systematic ex-
ploration of alternative target sites in enzymes of viral
and other pathogens with small molecules.
EXPERIMENTAL PROCEDURES
Small-Molecule Library
We used a commercially compiled library of 2500 structurally diverse
‘‘drug-like’’ compounds of many different compound classes (Com-
Genex, Hungary) that adhered to Lipinski’s ‘‘rule-of-five’’ [31]. Each
compound had a molecular weight below 550 Da.
Reporter Ribozyme Screening Assay
The screening assay was performed in 384-well plates. Each reaction
was carried out in total volume of 25 ml under multiple turnover condi-
tions with excess FRET substrate (200 nM) over the reporter ribozyme
FK-1 (10 nM) in HH buffer (50 mM Tris/HCl [pH 7.9], 25 mM NaCl) at
37C in the presence of HIV-1 RT (200 nM) and a small-molecule entity
(100 mM) from the library by using an automated liquid-handling sys-
tem (Tecan) with ceramic tips. The enzyme mixture had to be prepared
in Pyrex glass vials for robotic operation. After the plates were prein-
cubated for 15 min at 37C in an Ascent Fluoroskan apparatus, the ri-
bozyme reaction was initiated by adding MgCl2 to a final concentra-
tion of 8 mM. The cleavage reaction was monitored in real time by
measuring FAM-dye fluorescent emission (520 nm) for 15 min at 60 s
intervals at a fixed excitation wavelength (492 nm). Negative control
without HIV-1 RT was included for each compound. Each plate also
contained a standard ribozyme reaction without compound as a pos-
itive control. Reactions were done in duplicate. The initial velocity
(fluorescence/min) was determined by plotting the increment of fluo-
rescence intensity, multiplied by a factor of 10,000, versus time. For
each compound, the relative ribozyme activity (Arel) was calculated
by using the equation Arel = VRT+ /VRT (Arel = relative activity, VRT+ =
average number of initial velocity of ribozyme in the presence of
HIV-1 RT, VRT = average number of initial velocity of ribozyme in
the absence of HIV-1 RT). The standard reaction without compound
usually gave the Arel value of 0.2–0.3 depending on the plate. The com-
pounds that showed a value of Arel > 0.4 were identified as hits and
were selected for testing.
In Vitro Polymerase Inhibition Assay
The RNA-dependent DNA polymerase activity was assayed by moni-
toring the RNA template/DNA primer-directed incorporation of dNTPs,Chemistry & Biology 14,while the DNA-dependent DNA polymerase activity was assayed by
DNA template/DNA primer-directed incorporation of dNTPs. After
heat denaturing at 95C for 5 min (RNA template/DNA primer denatur-
ing at 70C), the DNA template (10 mM) was annealed to a 50-32P-end
labeled complementary DNA primer (3 mM) by slow cooling to room
temperature for 1 hr. The small-molecule inhibitors were preincubated
at 37C for 5 min at various concentrations in the enzyme mixture con-
taining 14 nM HIV-1 RT and 50 mM dNTP. Polymerase reactions were
carried out in 20 ml volumes, containing 50 mM Tris/HCl (pH 8.0),
50 mM KCl, and 10 mM MgCl2. The reactions were initiated by the
addition of DNA template/50-[32P]-DNA primer complex and incubated
at 37C for 15 min. The polymerase activity was deactivated by the
addition of 40 ml STOP solution (80% formamide, 20 mM EDTA) and
denatured by heating at 95C for 5 min prior to gel analysis (15% se-
quencing gel). The gel was visualized by autoradiography, and the
amount of DNA synthesized was quantified by phosphor imaging anal-
ysis. IC50 values were calculated from the inhibition dose-dependent
curves by using Origin software. Assays of HIV-2 RT, AMV, MMLV,
Klenow fragment, and human DNA polymerase b were carried out in
the buffers supplied by the manufacturers. The reaction time was elon-
gated to 1 hr for the Klenow fragment and human DNA polymerase b.
Optionally, the concentration of dNTP was increased to 200 mM.
HIV-1 Replication Assay
A total of 2 3 104 TZM cells were grown in a 48-well plate. Different
concentrations of compounds dissolved in 2 ml 100% DMSO were di-
luted in 150 ml cell culture medium (DMEM), then 50 ml virus containing
solution (= 10,000 infectious units; infectivity was determined as tissue
culture infectious dose 50% [TCID50] on C8166 cells) was added to
a final concentration of 1% DMSO. TZM cells were infected with
200 ml DMEM containing virus and inhibitor after removal of old medium.
After incubation for 2 days at 37C under 5% CO2 atmosphere, the
luciferase marker gene expression, under the control of the HIV-1
LTR promoter, was measured (Steady-Glo luciferase assay, Prom-
ega). NL4-3 that had been produced in a coculture with C8166 cells
was used as virus.
Infectivity Assay
Fresh coculture was prepared by dilution of coculture of NL4-3 virus
with uninfected MT4 cells in the ratio of 1:10 (1 3 106 MT4/ml). After
4 hr of incubation at 37C under 5% CO2 atmosphere, 500 ml coculture
and 5 ml different concentrations of inhibitors were added to each 48
well. After 2 days at 37C under 5% CO2, cell-free supernatant of the
MT4 coculture was used to infect TZM cells, which enables the deter-
mination of the amount of infectious particles that have been produced
in the presence of inhibitor. A total of 2 days postinfection, cells were
fixed with 3% PFA for 30 min and were washed with PBS. The infected
TZM cells were stained with b-galactosidase substrate (TZM cells also
contain a b-galactosidase reporter gene under the control of HIV-1
LTR). After 2–3 hr of incubation at 37C, infected cells turned blue
and were counted under the microscope.
Residue Mapping and Structure Analysis
Structural and mutant data analyzed herein are summarized in Table
S1. For structure analysis and comparison, residue mapping, and
the generation of graphical representations, the Molecular Operating
Environment (MOE, Chemical Computing Group, Inc.; http://www.
chemcomp.com) was used.
Supplemental Data
Supplemental data include four figures and a table and can be found
with this article online at http://www.chembiol.com/cgi/content/full/
14/7/804/DC1/.
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